Journal article

Delay from treatment start to full effect of immunotherapies for multiple sclerosis

Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, Dana Horakova, Eva K Havrdova, Maria Trojano, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Grammond, Patrizia Sola, Diana Ferraro, Serkan Ozakbas, Roberto Bergamaschi Show all

BRAIN | OXFORD UNIV PRESS | Published : 2020


In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies reduce disease activity, the time required to attain maximal effect is unclear. In this study we aimed to develop a method that allows identification of the time to manifest fully and clinically the effect of multiple sclerosis treatments (‘therapeutic lag’) on clinical disease activity represented by relapses and progression-of-disability events. Data from two multiple sclerosis registries, MSBase (multinational) and OFSEP (French), were used. Patients diagnosed with multiple sclerosis, minimum 1-year exposure to treatment, minimum 3-year pretreatment follow-up and..

View full abstract


Awarded by NHMRC

Awarded by Agence Nationale de la Recherche

Funding Acknowledgements

This study was supported by the EDMUS Foundation, Biogen and NHMRC (1140766, 1129189, 1157717). I.R. is supported by a MSIF-ARSEP McDonald fellowship grant and a Melbourne Research Scholarship. The MSBase Foundation is a not-for-profit organization that receives support from Biogen, Novartis, Merck, Roche, Teva and Sanofi Genzyme. The Observatoire Francais de la Sclerose en Plaques (OFSEP) is supported by a grant provided by the French State and handled by the 'Agence Nationale de la Recherche,' within the framework of the 'Investments for the Future' program, under the reference ANR-10-COHO-002, by the Eugene Devic EDMUS Foundation against multiple sclerosis and by the ARSEP Foundation. The study was conducted separately and apart from the guidance of the sponsors.